Cancer Studies and Molecular Medicine Open Journal

Editorial Board


Cancer Studies and Molecular Medicine - Open Journal


               Editor-in-Chief

Pradeep Garg, PhD

Executive Director
Center for Molecular Imaging and Therapy
Biomedical Research Foundation of Northwest Louisiana
1505 Kings Highway
Shreveport, LA 71103, USA


Dr.Garg, PhD is the Executive Director of “Center for Molecular Imaging and Therapy” (CMIT), a subsidiary of Biomedical Research Foundation of Northwest Louisiana, Shreveport, LA (BRF). Prior to his joining BRF, Dr. Garg was Professor of Radiological Sciences and Director of PET research Center at Wake Forest University School of Medicine, Winston Salem, NC, USA. Prior to Wake Forest University Health Sciences, Dr. Garg worked at Duke University Medical Center (1987-1995) and then moved as a faculty in the Department of Radiology at Yale University Medical Center, New Haven, CT (1995-2003) where he later became the Director of the Yale University PET Center.
Dr. Garg is a Molecular Imaging Scientist with research focus in the development and evaluation of novel radiopharmaceuticals as diagnostic and/or therapeutic agents. One of the major strength of his research is his ability to carry out research from bench to bedside. His research focus could be categorized into three major focus areas viz. Oncology, Cardiac and Neurobiology studies. His laboratory has developed novel methods to incorporate bioactive functional groups and radionuclides into a variety of small molecules of biological interest, monoclonal antibodies, single chain proteins, peptides, and amino acids. He participated in multiple clinical trials that ranged from studying imaging probes as tool to monitor therapeutic efficacy in patient, assessing prognostic value of molecular imaging probes in patients with cancers such as prostate and esophageal cancer, to early diagnosis of Alzheimer disease. His group has been very active in developing imaging probes for a variety of neurological dysfunctions and has extensive work experience interrogating dopaminergic, serotonergic and norepinephrine systems. His research collaborators include basic science researchers as well as clinicians and clinical researchers.
He has published extensively in national and international journals. He served on numerous national and international committees. He is a member of several professional organizations such as Society of Nuclear Medicine and Molecular Imaging, Society of Radiopharmaceutical Sciences, American Chemical Society, and American Association for Cancer Research. He served as Board member and as President of the Radiopharmaceutical Science Council of the Society of Nuclear Medicine and Molecular Imaging. He is on editorial board of several journals and is an active reviewer for a variety of national and international journals.


               Associate Editors

Jennifer Sims-Mourtada, PhD

Senior Clinical Scientist
Center for Translational Cancer Research
Helen F. Graham Cancer Center
Christiana Care Health System
Newark, DE, USA


Dr. Sims-Mourtada is the Director of Translational Breast Cancer Research in the Center for Translational Research at the Helen F Graham Cancer Center and Research Institute, Christiana Care Health Services, Inc, located in Newark, DE. She is also an appointment as a adjunct Associate Professor in the Department of Medical Laboratory Sciences, College of Health Sciences at the University of Delaware. She received her PhD in Immunology in 2004 from the University of Texas Graduate School of Biomedical Sciences and completed her post-doctoral training in Radiation Biology at The University of Texas MD Anderson Cancer Center. Prior to joining the HFGCCRI, she served as Director of Molecular Research and Development for RadioMedix, Inc. located in Houston TX.


               Editors


Walter A. Hall, MD, MBA

Professor
Department of Neurosurgery
SUNY Upstate Medical University
750 East Adams Street
Syracuse, NY 13210, USA


Dr. Hall is a Professor of Neurosurgery at the State University of New York Upstate Medical University in Syracuse, New York. Prior to his arrival in Syracuse in 2007, he was a Professor of Neurosurgery, Radiation Oncology, and Radiology at the University of Minnesota School of Medicine and the Shelly N. and Jolene J. Chou Chair in Neurosurgery. Dr. Hall received his BA degree from Columbia College of Columbia University in 1979 and his MD degree from the College of Physicians and Surgeons of Columbia University in 1983. He completed his General Surgery Internship at the University of Pittsburgh in 1984 and his neurosurgical residency was completed at the University of Pittsburgh in 1990. During his training, he spent two years at the National Institutes of Health in the Surgical Neurology Branch as a Medical Staff Fellow from 1987 to 1989. He was the 1990 recipient of the Van Wagenen Fellowship of the American Association of Neurological Surgeons which he spent working in the Department of Tumor Biology of the Norwegian Radium Hospital in Oslo, Norway. Dr. Hall joined the faculty of the University Of Minnesota School of Medicine in February 1991. In 1996 he was awarded the Mahaley Clinical Research Award in brain tumors by the Joint Section of Tumors of the Congress of Neurological Surgeons and the American Association of Neurological Surgeons. In 1998, Dr. Hall received his MBA degree from the Carlson School of Management of the University of Minnesota. He was the Director of the Brain Tumor Center of Minnesota and has extensive clinical and laboratory experience in developing new therapeutic modalities for treating brain tumors. Treatment modalities for brain tumors that have been developed under Dr. Halls guidance include stereotactic radiosurgery, fractionated stereotactic radiotherapy, blood-brain barrier disruption chemotherapy, interventional magnetic resonance imaging-guided neurosurgery, and targeted toxin therapy. He performed more that 1,000 neurosurgical procedures using intraoperative magnetic resonance imaging guidance over from 1997 to 2007. In addition, Dr. Hall has authored more than 180 publications on brain tumors, targeted toxins, intraoperative magnetic resonance imaging-guided neurosurgery, and central nervous system infections.

Frank S. Lieberman, MD

Professor
Department of Neurology
University of Pittsburgh School of Medicine
5150 Centre Avenue, Rm 561
Pittsburgh, PA 15232, USA


Dr. Lieberman has been active clinical translational investigators focusing on develop of novel therapies for patients with malignant and low grade gliomas since 1985. He has extensive experience in the design, conduct, and interpretation of translational clinical trials of conventional cytotoxic drugs, molecularly targeted agents, and immunotherapeutic strategies. His clinical and translational research efforts have encompassed the application of molecular neuropathology and neuroimaging to strategies for personalized, molecularly targeted therapies for patients with primary central nervous system tumors. He currently serve as the director of the adult neurooncology program within the University of Pittsburgh Cancer Institute, where he oversee the design and conduct of clinical trials for patients with primary and metastatic brain tumors. He currently serve as our institution’s principal investigator for participation in the Adult Brain Tumor Consortium, NRG Consortium, the Collaborative Ependymoma Research Network, and ECOG-ACRIN. He serves on the CNS Tumor Committee of NRG and ECOG- ACRIN, the Biomarker and Experimental Imaging committees for ECOG-ACRIN, and the imaging committee for the ABTC. He had served as principal investigator as well as co-investigator in innovative glioma vaccine trials, for both high grade and low grade gliomas. He had a national leadership role in the translational imaging efforts to develop imaging biomarkers for treatment response in oncology clinical trials, focusing on malignant gliomas. He served as co-investigator (with James Mountz) for our institutional Quantitative Imaging Network U01 project assessing novel PET tracers and high field strength MRI spectroscopy and dynamic contrast imaging as early biomarkers of response in clinical trials for newly diagnosed and recurrent glioblastoma. He is a co-investigator for the QIN proposal expanding this work to evaluation of imaging biomarkers of response in immunotherapy trials for high grade gliomas. He served as chair of the working group for Clinical Trials Design and Development for the Quantitative Imaging Network and as a liaison between QIN and the NCI collaborative trial groups. He has been an institutional leader in the application of molecular profiling to management of patients with low grade gliomas, with our institution beginning molecular profiling of all gliomas beginning in 2002 with FISH and PCR based LOH analysis and more recently with next generation sequencing. He is an active participant in our institutional phase 1 program, specifically focusing on expanding phase 1 option for patients with malignant gliomas, through the use of molecular profiling.

Myriam N. Bouchlaka, PhD

Post Doctoral Fellow
Immunotherapy and Hematopoietic Stem Cell Transplant Research Group (Capitini)
University of Wisconsin-Madison
1111 Highland Ave, WIMR 4136
Madison, WI 53705, USA


EDUCATION

•(2011) PhD, Cellular and Molecular Biology, University of Nevada, Reno, School of Medicine
Advisor: William J. Murphy, PhD
Thesis: Cancer Immunotherapy: Limitations and Potential Strategies
•(2007) BS, Biology, University of Nevada, Reno, NV
Minor: Chemistry

Chatchawin Assanasen, MD

Director, UT Southeast Asian Pediatric Hematology Oncology Program
CCRI Distinguished Chair in Pediatric Oncology
Associate Professor
Department of Pediatric Hematology/Oncology
University of Texas Health Science Center at San Antonio
7703 Floyd Curl MC 7810
San Antonio, TX 78229, USA


EDUCATION:

Year Degree Discipline Institution/Location

• 1996 MD Medicine St. Georges University, School of Medicine, Bay Shore, NY, USA
• 1990 BA Natural Science University of Pennsylvania, Philadelphia, PA, USA


TRAINING:

Fellowship

• 2000-2003, Pediatric Hematology/Oncology in University of Texas Southwestern Medical Center, Dallas, TX, USA


Residency

• 1996-1999, Pediatrics in University of Florida College of Medicine, Health Science Center, Jacksonville, FL, USA


ACADEMIC APPOINTMENTS:

• (08/2012 - Present): Distinguished Chair in Pediatric Oncology, Childrens Cancer, Research Institute, University of Texas Health Science Center, Department of Pediatrics, San Antonio, TX
• (09/2011 - Present): Associate Professor/Clinical Non-Tenured and Medical Director, South Texas Pediatric Blood and Cancer Center, University of Texas Health Science Center, Department of Pediatrics, San Antonio, TX
Details: Pediatric Hematology & Oncology
• (02/2011 - 08/2011): Assistant Professor/ Clinical Non-Tenured and Medical Director, Howard A. Britton MD Childhood Cancer and Blood Disorders Center, University of Texas Health Science Center, Department of Pediatrics, San Antonio, TX
Details: Pediatric Hematology & Oncology
• (11/2010 - 01/2011): Adjunct Clinical Assistant Professor, Lake Erie College of Osteopathic Medicine, Department of Pediatrics, Bradenton, FL
• (01/2006 - 01/2011): Clinical Assistant Professor Florida State University College of Medicine, Department of Pediatrics, Tallahassee, FL

Saeed Sadeghi, MD

Associate Clinical Professor
Division of Hematology-Oncology
David Geffen School of Medicine
University of California
Los Angeles, CA 90095, USA


EDUCATION:

•(1991-1995) BS, University of California, Los Angeles
•(1995-1999) MD, St. Louis University School of Medicine


Internship

•(1999-2000) LAC/USC Medical Center, Keck School of Medicine at USC


Residency

•(2000-2002) LAC/USC Medical Center, Keck School of Medicine at USC


Fellowship-Hematology-Oncology

•(2002-2005) David Geffen School of Medicine at UCLA


PROFESSIONAL EXPERIENCE:

Current Academic Appointment

(2012-Present) Associate Clinical Professor, David Geffen School of Medicine at UCLA, Division of Hematology-Oncology


Previous Academic Appointments

(2005-2012) Assistant Clinical Professor, David Geffen School of Medicineat UCLA, Division of Hematology-Oncology


Current Administrative Appointment(s)

(2005-Present) Medical Director, UCLA Santa Monica Hematology & Oncology Practice

Sun-Young Kong, MD, PhD

Associate Professor
Department of System Cancer Science, GCSP
Chief, Translational Epidemiology Branch, Research Institute
National Cancer Center/Department of laboratory Medicine
National Cancer Center
Goyang, Gyeonggi, Republic of Korea, South Korea


EDUCATION AND TRAINING

•(2005) PhD(Laboratory Medicine), College of Medicine, Sungkyunkwan University, Seoul, Republic of Korea
•(2001) MS (Laboratory Medicine), College of Medicine, Ewha Womens University, Seoul, Republic of Korea
•(1997) MD (Laboratory Medicine), College of Medicine, Ewha Womens University, Seoul, Republic of Korea


PROFESSIONAL EXPERIENCES

•(2005-Present) Faculty: Research Institute & Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea
•(2009-2011) Research Fellowship: Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
•(2003-2005) Fellowship: Laboratory Medicine, Research Institute & Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea
•(2002-2003) Fellowship: Laboratory Medicine, Samsung Medical Center, Sungkyunkwan Univesity, Seoul, Republic of Korea
•(1998-2002) Residency: Laboratory Medicine, Samsung Medical Center, Sungkyunkwan Univesity, Seoul, Republic of Korea
•(1997-1998) Internship: Medicine, Samsung Medical Center, Sungkyunkwan Univesity, Seoul, Republic of Korea

Young Kwang Chae, MD, MPH, MBA

Assistant Professor
Northwestern Medicine Developmental Therapeutics Institute
Division of Hematology and Oncology
Department of Medicine
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
645 N. Michigan Ave. Suite 1006
Chicago, IL 60611, USA


Dr. Chae is a translational and clinical investigator focusing on novel drug and biomarker development in early phase clinical trials in oncology. His plan is to bridge the gap between the cutting edge science and clinical medicine. His interest is in personalized precision medicine, novel combination therapy including immunotherapies and targeted therapies, rational clinical trial design and implementation in first in human clinical trials, and bio-correlatives that can help select patients predicted to have higher responses and lower toxicities to targeted therapies.

Shreya Kanodia, PhD

Associate Director, Administration
Department of Biomedical Sciences
Samuel Oschin Comprehensive Cancer Institute
USA


Dr. Shreya Kanodia is a cancer immunologist who has worked on developing therapeutic cancer vaccines since 1999. Trained as a tumor immunologist, she has over 15 years of life science research experience, including working on Phase I/II clinical trials for cancer therapy. Dr. Kanodia currently serves as Assistant Professor and Director of Grants Management in the Department of Biomedical Sciences and Associate Director for Administration in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center in Los Angeles, CA as well as Adjunct Assistant Professor at the University of Hawaii Cancer Center, Honolulu, HI. Her research interests lie in understanding the pathogenesis of mesothelioma and using this understanding to develop novel diagnostics and therapeutics. In addition to performing research, she has successfully established and operated a number of for-profit and not-for-profit organizations. She established the United States operations of Advanced Microdevices Pvt Ltd, a privately owned multinational corporation, and served as the Co-Owner/Director for Business Development. She also co-founded Advanced Bioscience Technologies LLC and functioned as the Co-Owner/Chief Financial Officer. She holds a Bachelors degree in Biochemical Engineering from the Indian Institute of Technology, Kharagpur in West Bengal, India and a Ph.D. in Immunology/Cancer Biology from the University of Texas M. D. Anderson Cancer Center in Houston, Texas.

Gokul Das, PhD

Associate Professor
Department of Pharmacology and Therapeutics
Center for Genetics and Pharmacology Building
Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, NY 14263, USA


Dr. Das is Associate Professor and Co‐Director of Breast Disease Site Research Group at Roswell Park Cancer Institute, Buffalo, New York. Dr. Das obtained Ph.D. from Baylor College of Medicine, Houston, Texas, followed by Postdoctoral research at the Cold Spring Harbor Laboratory, Long Island, New York. For the past twelve years, he has been a faculty member at the Roswell Park Cancer Institute, an NCI- designated Comprehensive Cancer Center. Dr. Das has extensive experience in cancer (especially breast cancer) in both basic and translational research arenas. He has gained experience in conducting both retrospective and prospective clinical studies. His laboratory uses cell culture and animal models along with patient tissues to investigate cellular and molecular mechanisms underlying the onset and progression of cancer and translating them to the clinic when possible. He is a principal investigator on the prospective clinical trial (originally funded by NCI) on the effect of estrogen receptor-p53 interaction on tamoxifen therapy in breast cancer patients.

Alexandros Charalabopoulos, MD, PhD, FRCS

Consultant Upper GI and General Surgeon
Mid Essex Hospital Services NHS Trust
Broomfield Hospital
Broomfield, Chelmsford
Essex CM1 7ET, UK


Consultant Upper GI & General Surgeon with an interest in Minimally Invasive Oesophagogastric Cancer Surgery.

Broomfield Hospital, Mid Essex Hospital Services NHS Trust


Permanent full time post from December 2013

As an Upper GI & General Surgery Consultant with a major interest in oesophagogastric cancer resection surgery, I perform all the operations in the spectrum of upper gastrointestinal surgery and mainly in the field of upper GI cancer surgery and its minimally invasive treatment. Broomfield Hospital is a high volume and the regional oesophagogastric cancer center in which more than 100 oesophagogastric resections per year are performed. I perform all types of oesophagectomies with the majority being laparoscopic assisted Ivor-Lewis oesophagogastrectomies and all the types of gastrectomies. Most of the elective operations I perform are laparoscopic. I perform upper GI and general surgical operations like laparoscopic incisional and inguinal (TEP and TAPP) hernia repair, laparoscopic cholecystectomy and CBD exploration, laparoscopic fundoplication, and laparoscopic Heller’s myotomy. I perform robotic upper GI surgery and especially robotic assisted Heller’s myotomy, robotic gastric resections and robotic gastric pacing. I also have a special interest in the treatment of gastroparesis and I am one of the two surgeons in the region who specializes in gastric pacing. I do general surgical on calls in a 1 in 8 rota. I perform upper GI diagnostic and therapeutic endoscopy and do upper GI and general surgical clinics. I am also a key member of the upper GI cancer MDT meetings.
As an Upper GI Surgeon I have been extensively trained in all types of oesophagectomies (Ivor-Lewis, McKeown, transhiatal, thoracoabdominal, minimal invasive), gastrectomies with extensive lymph node dissections (D1, D2 and even D3), bariatric surgery (gastric bypass, sleeve gastrectomy, gastric band, intragastric balloon) and laparoscopic benign upper GI disease. I have received expert training in Upper GI surgery from internationally renowned units. Specifically, cancer resections through fellowships from Broomfield Hospital in Chelmsford, National Cancer Centre Hospital in Tokyo, St Thomas’ Hospital in London and upper GI advanced laparoscopic procedures including bariatric surgery from St Thomas’ and St George’s Hospitals in London. I have also had advanced training in general surgery (mainly HPB, colorectal, endocrine, vascular) and was awarded an MSc and a PhD for my research in experimental acute pancreatitis and gastrointestinal carcinogenesis respectively. So far I have participated in about 3000 operations, the great majority of which is in the field of Upper GI surgery, having performed more than 1800 of those.

Daniel Dennis Taub, PhD, MT (ASCP) SH

Senior Scientist and Director
Center for Translational Studies, VA Medical Center
Department of Veteran Affairs, Veterans Health Administration
Medical Services, Bldg. 4, Room 1F-123A,
50 Irving Street, NW
Washington, DC 20422, USA

Dr. Dennis D. Taub received his Ph.D. from the Department of Microbiology and Immunology at Temple University School of Medicine in Philadelphia in 1991. He subsequently entered the laboratory of Dr. Joost J. Oppenheim as a staff fellow at the National Cancer Institute in Frederick, Maryland. From 1994-1997, he headed the vaccine monitoring laboratory within the Clinical Services Program at the National Cancer Institute. In early 1997, he moved to the National Institute on Aging and started the Laboratory of Immunology as its Chief as well as the Senior Investigator and Chief of Clinical Immunology Section. Dr. Taub also served as the Director of Clinical Core Laboratory and the NIA Bio-Repository, National Institute on Aging, National Institutes of Health from 1998-2010. In 2013, Dr. Taub moved to the Veterans Affairs Medical Center in Washington DC, Department of Veterans Affairs as the Director of Hematology and Immunology Research, Hematology Section.
Dr. Taub has wide interests in many areas of biology and medicine, both basic and clinical. His current researches focus on chemokine biology, age-associated changes in immune function, the role of cholesterol and lipid rafts in T lymphocyte signaling and trafficking, novel connections between the immune and endocrine systems, the molecular and biological mechanisms of age-associated thymic involution and the role of homocysteine in immunoregulation. He has published over 240 articles as an author or co-author in peer-reviewed journals, reviews and book chapters. Dr. Taub has rich experience in journal editorial services, including past experience as an Associate Editor for Journal of Clinical Investigation (2000-2002), Journal of Immunology (1995-2001), and Blood (2000-2005). He currently sits on the editorial board of numerous journals including Ageing Research Reviews, Brain, Behavior and Immunity, Cellular Immunology, Current Immunology Reviews, Journal of Gerontology (Medical Sciences), Journal of Immune Based Therapies and Vaccines, Journal of Neuroinflammation, Mechanisms of Ageing and Development, and several others. Dr. Taub is also the current Editor-in-Chief of the Journal of Inflammation, International Journal of Medical Sciences and the Journal of Immune-Based Therapies, Vaccines and Antimicrobials. He also serves as a member of Faculty 1000, and serves on many Committees/Advisory Boards within NIH or external.

Li Chen, PhD

Assistant Professor
Division of Cancer Biostatistics
Department of Biostatistics
College of Public Health and Biostatistics and Bioinformatics Shared Resource Facility
Markey Cancer Center
University of Kentucky, USA


Dr. Chen is an Assistant Professor of the Division of Cancer Biostatistics in the Department of Biostatistics and the Biostatistics and Bioinformatics Shared Resource Facility at the Markey Cancer Center, University of Kentucky. She received her PhD in Biostatistics from the University of North Carolina at Chapel Hill in 2009.

Ramachandran Murali, PhD

Associate Professor
Research Division of Immunology and Infectious Disease
Department of Biomedical Sciences
Cedars-Sinai Medical Center
8700 Beverly Boulevard
Davis Building 5091
Los Angeles, CA 90048, USA


EDUCATION AND POSTGRADUATE TRAINING

•(1978) BSc, University of Madras, India (Physics)
•(1980) MSc, University of Madras, India (Physics)
•(1986) PhD, University of Madras, India (Biophysics)
•(1986-1988) Postdoctoral Fellow, Columbia University, New York, NY
•(1988-1994) Postdoctoral Fellow, The Wistar Institute, Philadelphia
•(1994-1996) Postdoctoral Fellow, University of Pennsylvania


FACULTY APPOINTMENTS

•(1997-1999) Research Associate in Pathology and Laboratory Medicine, University of Pennsylvania
•(1999-2006) Research Assistant Professor of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine
•(2007-2010) Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine
•(2010-Present) Adjunct Associate Professor, Department of Pathology and Laboratory of Medicine, University of Pennsylvania, Philadelphia
•(2010-Present) Associate Professor, Dept. of Biomedical Sciences, Cedars-Sinai Medical Center, LA
•(2011-Present) Director, Molecular Therapeutics Core Facility, Cedars-Sinai Medical Center, LA

Khalid Al-Nedawi, PhD

Assistant Professor
Department of Medicine
McMaster University and St. Joseph’s Healthcare
50 Charlton Street East
Hamilton, Ontario, Canada


Dr. Al-Nedawi received his PhD in Medical Biology and Biotechnology. He received a post-doctoral fellowship and scientific adjunct position at the center for medical research at the Polish Academy of Science. He joined McGill University as a post-doctoral fellow and later as medical scientist and faculty lecturer. Dr. Al-Nedawi has received several awards and recognition for his scientific accomplishments. He is the winner of the 2010 Michael G. DeGroote academic fellowship award at McMaster University. Currently, Dr Al-Nedawi is an Assistant Professor at McMaster University/Department of Medicine.


RESEARCH:

Dr. Al-Nedawi has contributed to research on thrombosis haemostasis, cancer progression, angiogenesis, metastasis and biomarkers. Dr. Al-Nedawi’s primary interest is the mechanisms of intercellular interactions through short exosomes / microvesicles. Dr. Al-Nedawi reported the mechanism by which cancer cells can shed oncogenic proteins via microvesicles to the neighboring non-cancer cells providing them with an ectopic transformed phenotype. Furthermore, he reported the transfer of oncogenic proteins from cancer cells to tumour endothelial cells triggering the angiogenic switch. In addition, he contributed to the detection of oncogenic proteins in the cargo of microvesicles circulating in the cancer patient’s peripheral blood. Dr. Al-Nedawi has published in high ranked medical journals like “Blood, ATVB, NCB, PNAS”, and contributed to many international scientific conferences. Dr Al-Nedawi is funded by prostate cancer Canada (Movember foundation), and St Joseph’s Hospital. Dr Al-Nedawi lab located at St Joseph’s healthcare, Hamilton Center for Kidney Research. A postdoctoral fellow and four graduate students, currently working in Dr Al-Nedawi’s lab pursuing different research projects.

Sajeed Abdul Rahuman, DNB, DMRT, MD, MBBS, MRC

Associate Professor
Regional Cancer Centre
Medical College Campus
Thiruvananthapuram 695011, Kerala, India


Education and Training

• (2013) Phd Scholar Radiobiology, Faculty of Medicine, University of Kerala, Thiruvananthapuram, Kerala 695034, India
• (2002) DNB, Radiotherapy, Regional Cancer Centre, Trivandrum, University of Kerala, Thiruvananthapuram, Kerala 695034, India
• (2001) Regional Cancer Centre, Trivandrum, University of Kerala, MD, Nov 2001, Radiotherapy Thiruvananthapuram, Kerala 695034, India
• (2000) DMRT, Radiotherapy, Regional Cancer Centre, Trivandrum, University of Kerala, Thiruvananthapuram, Kerala 695034, India
• (1993) MBBS, Govt. Medical College, Trivandrum, University of Kerala, Thiruvananthapuram, Kerala 695034, India


Professional Experience

•(2013-Present) Associate Professor, Regional Cancer Centre, Medical College Campus, Thiruvananthapuram
•(2013-Present) Member, Faculty of Medicine, University of Kerala, Thiruvananthapuram
•(2010-2013) Assistant Professor, Regional Cancer Centre, Medical College Campus, Thiruvananthapuram
•(2004-2010) Lecturer in Radiotherapy, Regional Cancer Centre, Medical College Campus, Thiruvananthapuram
•(2003-2004) Specialist in Oncology, Insurance Medical Service
•(2002-2003) Research Medical Officer, Regional Cancer Centre( Deputation from Insurance Medical Service)
•(2001-2002) Assistant Insurance Medical Officer, Insurance Medical Service
•(1995-1996) Assistant Surgeon, Kerala Government Health Service

Jian Pan, PhD

Associate Professor
Department of Hematology and Oncology
Childrens Hospital of Soochow University
303 Jingde Rd, Ping Jiang Qu, Suzhou, Jiangsu, China


Education:

•(2001-2005) B.Sc. Biology , NanJing University, Jiansu Province, PR China
•(2005-2010) Ph.D. Immulogy, State Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China


Experience:

•(2010- Present) Associate professor, Department of Hematology and Oncology, Childrens Hospital of Soochow University, Suzhou, China
•(2010-Present) A guest professor of Translational Research Center, Second Hospital, The Second Clinical School, Nanjing Medical University, Nanjing, China
•8 years of extensive experiences in molecular oncology, hematology, leukemia and cell biologically associated research

Keechilat Pavithran, MD, DM, FRCP(L)

Professor and Head
Department of Medical Oncology
Amrita Cancer Institute
PO. AIMS Ponekkara
Cochin 682041, Kerala


Dr. Pavithran, has done MD in Internal Medicine from Calicut Medical College and DM in Medical oncology from Kidwai Memorial Institute of Oncology, Bangalore. He is the Fellow of the Royal college of Physicians of London. He had training in hematology from Royal Hallamshire Hospital, Sheffield, United Kingdom and gained experience in Bone-marrow transplantation from Fred Hutchinson cancer centre, Seattle, USA.
Currently, he is working as Professor and Head of the Department of Medical Oncology and Hematology at Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India, since 2004.
He is the Member of many national (ISHTM, ISMPO, ISO, API) and international organizations (International Medical sciences Academy, International Society of Geriatric Oncology, European Society of Medical Oncology, International Network for Cancer treatment and Research (INCTR) and International society of gynecologic oncology.
He has presented many papers and delivered many lectures at various national and international conferences. Has published 65 papers in International Journals and 82 in National journals. Edited two books on cancer and has contributed more than 37 chapters in various books. Participated in more than 25 clinical trials.
He is the Reviewer for Biomed Central (www.biomedcentral.com) journals, American journal of Clinical Oncology, Supportive oncology, Indian Journal of Cancer, Journal of Cancer Research and Experimental Oncology, Indian Journal of Medical & Pediatric Oncology, Journal of Association of Physicians of India, Indian Journal of Dermatology & Venereology, Indian Journal of Medical Sciences and Indian journal of Hematology and Transfusion Medicine. Also serves in the editorial board of many national and international journals.

Francis V. James, MD

Additional Professor
Department of Radiotherapy and Oncology
Regional Cancer Centre
Trivandrum, Kerala, India


EDUCATIONAL BACKGROUND


• (1983) MBBS, University of Kerala, India
• (1989) MD, University of Kerala, India


INTERNATIONAL TRAINING


• (June-December 1992) Fellowship of Leeds University, UK
• (1996-1997) Fellowship of Institute of Cancer Research, London and Honorary Senior Registrar in Uro-Oncology, Royal Marsden Hospital, London
• (February 2002-April 2003) Clinical Research Fellowship of Institute of Cancer Research in Uro-oncology, Royal Marsden Hospital, UK
• (Sept-Oct 2012) AROI Kirloskar Fellowship, Mount Vernon Hospital, Middlesex, UK


PROFESSIONAL EXPERIENCE


• (Since July 2004) Additional Professor of Radiotherapy and Oncology, Regional Cancer centre, Trivandrum
• (April 2003-June 2004) Associate Professor of Radiotherapy and Oncology, Regional Cancer Centre Trivandrum, India
• (February 2002-April 2003) Clinical Research Fellow, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
• (March 1998-January 2002) Associate Professor of Radiotherapy & Oncology, Regional Cancer Centre, Trivandrum, India
• (March 1997-March 1998) Assistant Professor of Radiotherapy, Regional Cancer Centre, Trivandrum, India
• (March 1996-February 1997) Clinical Research Fellow, Institute of Cancer Research & Honorary Senior Registrar, Royal Marsden Hospital, Sutton, UK
• (March 1995-February 1996) Assistant Professor of Radiotherapy, Regional Cancer Centre, Trivandrum, India
• (Dec 1992-March 1995) Lecturer in Radiotherapy ,Regional Cancer Centre, Trivandrum
• (June 1992-Dec 1992) Clinical Research Fellow, Cookridge Hospital, University of Leeds, UK
• (Aug. 1990-May 1992) Lecturer in Radiotherapy, Regional Cancer Centre, Trivandrum, India
• (Feb 1990-Aug 1990) Tutor in Radiotherapy, Medical College, Trichur, India
• (Dec 1988-Jan 1990) Tutor in Radiotherapy, Medical College, Trivandrum, India
• (June 1986-Apr 1989) Resident in Radiotherapy, Medical College, Trivandrum, India
• (Jan 1985-June 1986) Junior Medical Officer, Department of Medicine, Bishop Vayalil Medical Centre, Moolamattom, Kerala, India

Masahiko Tanabe, MD, PhD

Associate Professor
Department of Breast Oncology
Juntendo University School of Medicine
2-1-1 Hongo Bunkyo-ku
Tokyo 113-8421, Japan


Dr. Tanabe, Medicine Doctor (Ph.D.-medicine), now is an Associate professor of the Department of Breast Oncology at Juntendo University School of Medicine. He is a surgical oncologist for breast cancer as well as a certified specialist in medical genetics. He got his Medicine Doctor s degree (Ph.D.) at the University of Tokyo. Currently. Dr. Tanabe is delighted to collaborate with the Cancer Studies and Molecular Medicine -Open Journal (CSMMOJ). He can contribute to review manuscripts on epigenetic biology and clinical field of breast cancer.